Under the terms of this agreement, KYORIN has obtained exclusive rights to develop, manufacture,
and commercialize BDT272 in Japan, South Korea, and Taiwan. In consideration for these rights,
KYORIN will make payment to BIODOL up to 79 million euros based on upfront payment, milestone
payments related to the progress of development, regulatory approval and the achievement of certain
net sales targets. In addition, KYORIN will pay royalties to BIODOL based on net sales.
BDT272, completing Ph1 studies, is anticipated to demonstrate effective analgesic properties through
the inhibition of FLT3, a receptor tyrosine kinase implicated in the pathogenesis and maintenance of
pain condition such as neuropathic pain.
KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain as one of
our key strategic therapeutic area for research and development. KYORIN anticipates that this
innovative pain treatment candidate will provide a new treatment option for patients suffering from
pain conditions.
“This agreement further validates BIODOL’s business model, which is to advance BDT272 through
early- and mid-stage development and subsequently partner with established pharmaceutical
companies, such as KYORIN, that have proven capabilities in clinical development and commercial
deployment. This year of close collaboration with KYORIN’s teams has strengthened our confidence in
the quality of this partnership.” said Fabien GRANIER, CEO of BIODOL Therapeutics.
“Our partnership with BIODOL represents a powerful synergy that elevates our drug discovery pipeline
to new heights. We are fully dedicated to advancing our clinical program in Japan, driven by a shared
vision to redefined pain treatment and bring hope to those in need. This is a bold step forward in
KYORIN’s evolution.” said Yutaka OGIHARA, President and CEO of KYORIN Pharmaceutical Co., Ltd.
